Dr. Higano on Radium-223 for Prostate Cancer

Celestia Higano, MD
Published: Tuesday, Jun 27, 2017



Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Radium-223 was shown in a phase III trial to extend survival for patients with prostate cancer, explains Higano. Unlike the other radioisotopes which are used towards the end stage, it was shown that there was a survival benefit for those who received radium-223 in addition to best supportive care.



Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Radium-223 was shown in a phase III trial to extend survival for patients with prostate cancer, explains Higano. Unlike the other radioisotopes which are used towards the end stage, it was shown that there was a survival benefit for those who received radium-223 in addition to best supportive care.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x